Plenary Session 4A: IBD / Stomach / Small Intestine

10/30/2019

8:30 AM - 10:15 AM

Location: Stars at Night Ballroom - B2

Presenting Author(s)

Edward Barnes, MD, MPH

Chapel Hill, NC
Christopher Cao, MD

Resident Physician
Thomas Jefferson University Hospital
Philadelphia, PA
JG

Jonathan Galati, BS
David Graham, MD

Houston, TX
NL

Nan Lan, MD

Cleveland, OH
Harish Patel, MD

Bronx, NY
William Sandborn, MD

Professor of Clinical Medicine
University of California - San Diego, San Diego, CA, United States
La Jolla, CA, US

Presentations:

8:30 AM - 8:40 AM
A Quality Improvement Initiative to Reduce Insurance-Related Delays in Patient Access to Biologic Therapies for Inflammatory Bowel Disease
Jonathan S. Galati, BS
8:40 AM - 8:50 AM
Effects of Ustekinumab Maintenance Therapy on Endoscopic Improvement and Histologic Improvement in the UNIFI Phase 3 Study in Ulcerative Colitis
William J. Sandborn, MD – University of California - San Diego, San Diego, CA, United States
8:50 AM - 9:00 AM
Endoscopic Stricturotomy in the Treatment of Anal Stricture in Patients With Fecal Diversion
Nan Lan, MD
9:00 AM - 9:10 AM
RHB-104, a Fixed-Dose, Oral Antibiotic Combination Against Mycobacterium Avium Paratuberculosis (MAP) Infection, Is Effective in Moderately to Severely Active Crohn’s Disease
David Graham, MD
9:10 AM - 9:20 AM
Incidence of Venous Thromboembolic Events in Patients With Ulcerative Colitis Treated With Tofacitinib in the Ulcerative Colitis Clinical Development Program
William J. Sandborn, MD – University of California - San Diego, San Diego, CA, United States
9:20 AM - 9:30 AM
Black and White Patients With Inflammatory Bowel Disease Demonstrate Similar Biologic Use Patterns With Medicaid Insurance
Edward L. Barnes, MD, MPH
9:30 AM - 9:40 AM
The Impact of In-Hospital Palliative Unit on Percutaneous Gastrostomy Practice, Volume, and Outcomes
Harish Patel, MD
9:40 AM - 9:50 AM
The Socioeconomic Impact on Presentation and Clinical Course of Celiac Disease
Christopher Cao, MD – Thomas Jefferson University Hospital
9:50 AM - 10:00 AM
Rifabutin (RHB-105) Based Triple Therapy for Helicobacter pylori (HP) Infection Eradication: Results of Pivotal Phase 3 Multi-Center Study (ERADICATE Hp2)
David Graham, MD